Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if giving (Rituxan) rituximab with
90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma.
The safety of this combination treatment will also be studied.